Barcelona’s Biorce Secures $52M to Revolutionize Clinical Trials

Biorce, a biotechnology startup based in Barcelona, has successfully raised $52 million in Series A funding, a record for the Iberian healthtech and AI sector. This funding round, led by DST Global Partners, saw contributions from Norrsken VC, YZR Capital, and notable angel investors including Arthur Mensch, Albert Nieto, Paulo Rosado, and Nik Storonsky. This significant investment comes just six months after Biorce’s previous funding, underscoring investor confidence in the company’s innovative approach to clinical trials.

Clinical trials are notoriously expensive and time-consuming, with global costs surpassing $120 billion annually. A single protocol change can halt patient recruitment for weeks and add nearly €1 million to the overall costs. Miscommunication with regulatory bodies such as the FDA and EMA can further exacerbate delays and uncertainties. Biorce aims to overcome these challenges with its proprietary AI platform, Aika, designed to automate and enhance trial design.

Transforming Clinical Trials with AI

Founded by Pedro Coelho, Clara Bernardes, José Faria, and Diogo Pisoeiro, Biorce is focused on simplifying the clinical trial process. Aika leverages machine learning, statistical modeling, and natural language processing to streamline trial design. It analyzes clinical data, identifies risk patterns, and reduces costly modifications while ensuring adherence to high scientific standards.

The platform’s core strengths include an advanced AI architecture tailored for clinical research and development, a comprehensive database of over 1 million past trials, and predictive modeling capabilities to identify potential design issues. Aika is already being utilized in various fields such as oncology, neurology, and rare diseases, demonstrating its versatility across different research domains.

As the role of AI in clinical trial design grows, Biorce competes with firms like Owkin, Huma, and QuantHealth. While many of these companies focus on patient selection or outcome prediction, Biorce distinguishes itself by automating the trial design phase, which is often the most cumbersome and costly aspect of drug development.

Future Growth and Development Plans

The newly acquired funding will facilitate Biorce’s expansion into international markets, including the opening of an office in Austin, Texas. Additionally, it will bolster the company’s engineering and commercial teams and expedite the development of Aika.

Biorce plans to introduce new features by early 2026, which will include tools for contract management, budgeting, and operational planning. These enhancements aim to provide trial teams with greater control throughout the research process.

As Biorce continues to innovate within the clinical trial landscape, it remains committed to making these processes faster, more reliable, and accessible to a broader range of researchers and institutions. The company has yet to respond to inquiries regarding its diversity and inclusion initiatives at the time of publication.